Jounce Therapeutics Inc (NASDAQ:JNCE) insider Hugh M. Cole acquired 1,900 shares of the business’s stock in a transaction on Friday, June 15th. The shares were bought at an average cost of $7.84 per share, with a total value of $14,896.00. Following the completion of the acquisition, the insider now owns 1,900 shares of the company’s stock, valued at approximately $14,896. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ:JNCE opened at $7.93 on Tuesday. Jounce Therapeutics Inc has a twelve month low of $6.92 and a twelve month high of $29.25. The firm has a market capitalization of $257.27 million, a PE ratio of -13.91 and a beta of 5.55.
Get Jounce Therapeutics alerts:Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Wednesday, May 9th. The company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.09). Jounce Therapeutics had a negative net margin of 47.73% and a negative return on equity of 19.90%. The business had revenue of $11.20 million during the quarter, compared to analyst estimates of $13.33 million. sell-side analysts predict that Jounce Therapeutics Inc will post -1.54 EPS for the current year.
A number of analysts have recently weighed in on the company. Cowen lowered Jounce Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 5th. Robert W. Baird lowered their target price on Jounce Therapeutics from $35.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, June 4th. JPMorgan Chase & Co. lowered Jounce Therapeutics from an “overweight” rating to a “neutral” rating and set a $12.00 target price for the company. in a research note on Monday, June 4th. Wells Fargo & Co lowered their target price on Jounce Therapeutics to $10.00 and set a “market perform” rating for the company in a research note on Thursday, May 31st. Finally, TheStreet lowered Jounce Therapeutics from a “c-” rating to a “d+” rating in a research note on Tuesday, May 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $15.00.
Several large investors have recently made changes to their positions in JNCE. SG Americas Securities LLC acquired a new stake in shares of Jounce Therapeutics in the fourth quarter valued at $294,000. Swiss National Bank increased its position in Jounce Therapeutics by 84.3% in the fourth quarter. Swiss National Bank now owns 24,700 shares of the company’s stock worth $315,000 after purchasing an additional 11,300 shares during the period. Wells Fargo & Company MN increased its position in Jounce Therapeutics by 101.7% in the fourth quarter. Wells Fargo & Company MN now owns 41,908 shares of the company’s stock worth $534,000 after purchasing an additional 21,127 shares during the period. Rhumbline Advisers acquired a new stake in Jounce Therapeutics in the fourth quarter worth about $134,000. Finally, Bank of New York Mellon Corp increased its position in Jounce Therapeutics by 10.8% in the fourth quarter. Bank of New York Mellon Corp now owns 45,889 shares of the company’s stock worth $585,000 after purchasing an additional 4,467 shares during the period. Institutional investors own 91.55% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
No comments:
Post a Comment